所有图片(1)
别名:
Ansamycin, Ansatipine (Farmitalia), LM-427, Mycobutin (Farmitalia)
经验公式（希尔记法）:
C46H62N4O11
推荐产品
等级
pharmaceutical primary standard
API类
rifabutin
制造商/商品名称
EDQM
应用
pharmaceutical (small molecule)
格式
neat
储存温度
2-8°C
InChI
1S/C46H62N4O11/c1-22(2)21-50-18-16-46(17-19-50)48-34-31-32-39(54)28(8)42-33(31)43(56)45(10,61-42)59-20-15-30(58-11)25(5)41(60-29(9)51)27(7)38(53)26(6)37(52)23(3)13-12-14-24(4)44(57)47-36(40(32)55)35(34)49-46/h12-15,20,22-23,25-27,30,37-38,41,49,52-54H,16-19,21H2,1-11H3,(H,47,57)/b13-12+,20-15+,24-14-/t23-,25+,26+,27+,30-,37-,38+,41+,45-/m0/s1
InChI key
ATEBXHFBFRCZMA-VXTBVIBXSA-N
正在寻找类似产品? 访问 产品对比指南
一般描述
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.
应用
Rifabutin EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
生化/生理作用
Rifabutin is an antibiotic; antitumor. Rifabutin interferes with HSP-90 molecular chaperone, enhances ubiquitination and protein degradation, and inactivates bacterial RNA polymerase.
包装
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他说明
Sales restrictions may apply.
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
监管及禁止进口产品
R E Chaisson
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 22 Suppl 1, S61-S66 (1996-04-01)
Patients with advanced human immunodeficiency virus (HIV) disease are at risk for infections caused by protozoa, fungi, viruses, bacteria, and mycobacteria. Chemoprophylaxis is being used increasingly to prevent a growing number of opportunistic infections that occur in HIV-infected patients. Multiple
B Dautzenberg
Infection, 25(1), 63-66 (1997-01-01)
The MICs of rifabutin on Mycobacterium avium are compatible with its efficacy in clinical infections. Two North American trials established the prophylactic effect of rifabutin in disseminated M. avium disease in AIDS patients. Several prospective non-randomized trials show the clinical
Anne M Baciewicz et al.
The American journal of the medical sciences, 335(2), 126-136 (2008-02-16)
Rifampin is a potent inducer of cytochrome P-450 oxidative enzymes as well as the P-glycoprotein transport system. Several examples of well-documented clinically significant interactions include warfarin, oral contraceptives, cyclosporine, itraconazole, digoxin, verapamil, nifedipine, simvastatin, midazolam, and human immunodeficiency virus-related protease
G Davies et al.
The Cochrane database of systematic reviews, (4)(4), CD005159-CD005159 (2007-10-19)
Rifamycins are an essential component of modern short-course regimens for treating tuberculosis. Rifabutin has favourable pharmacokinetic and pharmacodynamic properties and is less prone to drug-drug interactions than rifampicin. It could contribute to shortening of therapy or simplify treatment in HIV-positive
Is rifabutin prophylaxis against Mycobacterium avium complex infection in HIV infection worthwhile? The net impact on patients suggests not.
J M Stephenson et al.
Genitourinary medicine, 72(4), 272-276 (1996-08-01)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门